Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia

Standard cytotoxic induction chemotherapy for acute myeloid leukemia (AML) results in prolonged neutropenia and risk of infection. Romyelocel-L is a universal, allogeneic myeloid progenitor cell product being studied to reduce infection during induction chemotherapy. PATIENTS AND METHODS: One hundre...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Pinkal M., Brown, Janice, Gill, Saar, Solh, Melham M., Akard, Luke P., Hsu, Jack W., Ustun, Celalettin, Andreadis, Charalambos, Frankfurt, Olga, Foran, James M., Lister, John, Schiller, Gary J., Wieduwilt, Matthew J., Pagel, John M., Stiff, Patrick J., Liu, Delong, Khan, Irum, Stock, Wendy, Kambhampati, Suman, Tallman, Martin S., Morris, Lawrence, Edwards, John, Pusic, Iskra, Kantarjian, Hagop M., Mamelok, Richard, Wong, Alicia, Van Syoc, Rodney, Kellerman, Lois, Panuganti, Swapna, Mandalam, Ramkumar, Abboud, Camille N., Ravandi, Farhad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500663/
https://www.ncbi.nlm.nih.gov/pubmed/34156898
http://dx.doi.org/10.1200/JCO.20.01739

Ejemplares similares

Ejemplares similares